#United States #SK Life Science #Paramus #Neurology #Epilepsy Connect

Introduction

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., has made a significant stride in epilepsy management by launching Epilepsy Connect. This innovative digital platform is designed specifically for advanced practice providers (APPs), providing them with access to vital educational resources, accredited continuous medical education (CME), and networking tools essential for effective epilepsy care.

Addressing a Critical Need

With approximately 3.4 million individuals in the U.S. grappling with epilepsy, the role of APPs has become increasingly pivotal in delivering comprehensive healthcare. The launch of Epilepsy Connect aims to address the educational gaps experienced by these providers, fostering a better-informed and equipped workforce that can significantly enhance patient care.

Lisa Finnerty Lester, Vice President of Commercial Excellence at SK Life Science, emphasized the importance of supporting APPs, stating, "Advanced practice providers are an essential part of the epilepsy care team, and their role continues to grow as they help meet the needs of patients across diverse care settings."

Key Features of Epilepsy Connect

Complimentary Access to Valuable Resources

Enrollment in Epilepsy Connect is complimentary for U.S. APPs, granting them full access to a variety of resources tailored for epilepsy care. Here are the primary offerings:

1. Educational Courses: Focused learning modules that cover essential aspects of epilepsy management such as neuroanatomy, seizure classifications, treatment options, and effective communication strategies with patients.

2. Accredited Webinars: Live and on-demand CME programs furnished by Medscape provide the flexibility for APPs to engage in high-quality, relevant learning aligned with their clinical practices.

3. APP Connect: This peer networking feature allows APPs to forge connections, share insights, and support one another by exchanging knowledge and experiences within their field.

Empowering Patient-Centric Care

The need for resources like Epilepsy Connect is underscored by findings from SK Life Science's Hope, Hesitancy, and Hard Truths survey. The survey revealed a disparity in treatment discussions among healthcare professionals; for instance, only 65% of epileptologists, compared to lower percentages of APPs, regularly discuss alternative treatment options with patients. Despite this, a staggering 90% of patients expressed a desire to explore treatment changes, highlighting the urgency for expanded educational outreach.

Through Epilepsy Connect, SK Life Science seeks to fill this gap, empowering APPs to confidently engage with patients about their treatment plans, alternatives, and the management of their conditions.

Ongoing Commitment to Epilepsy Education

This initiative emphasizes SK Life Science's ongoing commitment to enhancing awareness and education surrounding epilepsy. It also aligns with the company's goal to strengthen the community of APPs as key contributors in patient care management. Epilepsy Connect is a direct response to ensuring that APPs are well-informed and equipped with the necessary tools to provide informed, confident treatment options for their patients.

Conclusion

In conclusion, Epilepsy Connect stands as a testament to SK Life Science, Inc.'s dedication to supporting advanced practice providers. By enhancing their education and resources, the platform aims to improve the overall quality of epilepsy treatment and patient outcomes across the United States. For more information or to enroll, visit Epilepsy Connect.